• Zoledronic Acid: Optimizing Cancer and Bone Disease Research

  2026-06-04

  Zoledronic Acid, a potent nitrogen-containing bisphosphonate from APExBIO, empowers researchers with precise control over cancer cell apoptosis and osteolytic bone disease models. Discover how to streamline applied protocols, troubleshoot common pitfalls, and leverage recent mechanistic insights for maximal translational impact.

• E-4031: Strategic Insights for Translational Cardiac Electro

  2026-06-03

  Explore how E-4031, a potent hERG potassium channel blocker, is reshaping translational cardiac electrophysiology research. This article delivers mechanistic clarity, experimental best practices, and strategic guidance for modeling proarrhythmic risk, with context from recent literature and APExBIO's commitment to research integrity.

• UHRF1-Mediated DNA Methylation Alters Osteogenesis in SOP

  2026-06-03

  This study uncovers how UHRF1-driven DNA 5-mC modifications alter super-enhancer landscapes in mesenchymal stem cells, impeding osteogenesis via the TGM2-autophagy axis in senile osteoporosis. These findings illuminate a mechanistic bridge between epigenetic regulation, enhancer redistribution, and bone loss, providing new avenues for targeted research and intervention.

• Palonosetron Hydrochloride: Selective 5-HT3 Antagonist Bench

  2026-06-02

  Palonosetron hydrochloride is a highly selective 5-HT3 receptor antagonist characterized by subnanomolar potency and an extended half-life, enabling robust prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. Its dual-site receptor binding and minimal off-target activity make it a gold-standard control for transporter and receptor studies.

• Discovery of ATG9A and PTOV1 as 14-3-3 Binding Partners in C

  2026-06-02

  This study identifies ATG9A and PTOV1 as novel 14-3-3 binding proteins and elucidates their roles in basal autophagy and oncogenic signaling. The mechanistic insights into their regulation highlight new avenues for understanding cancer cell survival and potential therapeutic intervention.

• iPSC-Based Drug Testing Platform for Cystic Fibrosis Variant

  2026-06-01

  This study introduces a multimodal induced pluripotent stem cell (iPSC) platform for assessing cystic fibrosis (CF) therapies across diverse CFTR genotypes. The work establishes robust, translational in vitro assays that model patient-specific CFTR dysfunction, enabling targeted drug evaluation and accelerating preclinical discovery for rare CF variants.

• AZ505: Potent SMYD2 Inhibitor for Translational Epigenetic R

  2026-06-01

  AZ505 stands out as a highly selective SMYD2 inhibitor, enabling precise modulation of histone and non-histone methylation in cancer and fibrosis models. Its substrate-competitive mechanism and robust selectivity empower researchers to dissect epigenetic regulation with confidence, especially in complex cellular and translational workflows.

• X-Gal in Functional Genomics: Beyond Blue-White Screening

  2026-05-31

  Explore X-Gal’s (5-bromo-4-chloro-indolyl-β-D-galactopyranoside) pivotal role in modern functional genomics, from advanced blue-white screening to decoding sensory gene regulation. This article delivers a unique, science-driven perspective on X-Gal assay innovation, bridging molecular cloning with emerging olfactory research.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-05-30

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and autologous stromal cell subpopulations, closely recapitulating the cellular heterogeneity and microenvironment of primary tumors. The findings underscore the model's utility for investigating tumor–stroma interactions, drug response variability, and resistance mechanisms, advancing the field of personalized preclinical cancer research.

• Rosiglitazone (Brl-49653): Applied PPARγ Workflows & Trouble

  2026-05-29

  Rosiglitazone (Brl-49653) is a gold-standard synthetic thiazolidinedione PPARγ agonist, enabling precise control over adipogenesis and insulin sensitivity in advanced metabolic research. This article delivers actionable, protocol-driven workflows and troubleshooting insights for leveraging APExBIO's high-purity Rosiglitazone across cell and animal models.

• Hexetidine (NSC-17764): Evidence, Mechanisms, and Protocols

  2026-05-29

  Hexetidine (NSC-17764) is a broad-spectrum antimicrobial agent validated for oral infection control. Its efficacy against Gram-positive and Gram-negative bacteria, as well as Candida albicans, is supported by reproducible MIC benchmarks and synergistic studies. This review provides machine-readable evidence on mechanisms, application boundaries, and workflow integration.

• UHRF1-Mediated DNA Methylation Alters Osteogenesis in Senile

  2026-05-28

  This study uncovers how UHRF1-driven DNA methylation orchestrates super-enhancer redistribution in mesenchymal stem cells, disrupting osteogenic differentiation in senile osteoporosis. The findings illuminate the UHRF1–TGM2–autophagy axis as a mechanistic bridge between epigenetic regulation and impaired bone formation, highlighting new avenues for targeted osteoporosis intervention.

• SlSLAH1-Mediated Malate Exudation Drives Aluminium Tolerance

  2026-05-28

  This study identifies the plasma membrane anion channel SlSLAH1 as a critical transporter for malate exudation and aluminium tolerance in tomato. It reveals how the SlSTOP1-SlSZP1 regulatory complex and SlSLAH1-SlSLAH2 heteromeric channels orchestrate an adaptive response, providing mechanistic insight into aluminium detoxification and opportunities for breeding tolerant cultivars.

• High-Throughput Identification of TB DHFR Inhibitors via Mac

  2026-05-27

  Santa Maria et al. present a machine learning-integrated framework that links high-throughput phenotypic and biophysical screening data to unravel mechanisms of action and prospectively identify potent inhibitors of Mycobacterium tuberculosis dihydrofolate reductase. This approach enables more precise discovery of antibacterial agents and offers insights applicable to other bacterial infection models.

• Rotigotine Hydrochloride: Dopamine D2/D3 Agonist in PD Resea

  2026-05-27

  Rotigotine hydrochloride stands out as a versatile dopamine D2/D3 receptor agonist for modeling both motor and non-motor complications of Parkinson’s disease. This guide delivers actionable workflows, data-backed parameters, and troubleshooting insights, bridging translational studies with experimental reproducibility.

454 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page